SecBot SecBot

PBM Oversight Act of 2023

S. 2406 Sen. Thomas Carper (D-DE) In committee
  1. Introduced Jul 20
  2. Committee Jul 20
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jul 20, 2023Next: Senate vote
1196d ago Jul 20, 2023: Read twice and referred to the Committee on Finance.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Member trades
3trades in the last 90 days
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Financials 1
Search all 1 companies, their asks and price moves Subscribe

Summary

PBM Oversight Act of 2023

Full summary3 paragraphs

This bill requires prescription drug plan (PDP) sponsors under the Medicare prescription drug benefit to report certain information about the involvement of affiliated committees in decisions about formularies.

Specifically, PDP sponsors that use formularies must report to the Centers for Medicare & Medicaid Services the names and descriptions of committees that are affiliated with the PDP sponsor, or a contracted pharmacy benefit manager, that are authorized to change initial recommendations of the pharmacy and therapeutic committee about formularies. PDP sponsors must also report any formulary changes that were made by an affiliated committee and provide justifications for these decisions.

The Government Accountability Office must report on the use of these types of committees with respect to formularies under the Medicare prescription drug benefit, including decision-making trends.

Library of Congress summary, Jul 20, 2023

Summary versions
  • Introduced in SenateJul 20, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.